Deals this week: CRISPR, Dragonfly Therapeutics, Roivant Sciences

16th November 2018 (Last Updated November 16th, 2018 00:00)

CRISPR Therapeutics will develop novel immune-oncology therapies after entering an agreement to use MaxCyte's cell engineering platform.

CRISPR Therapeutics will develop novel immune-oncology therapies after entering an agreement to use MaxCyte's cell engineering platform.

The partnership is an expansion of a deal signed by the two companies in 2017 for the use of MaxCyte’s flow electroporation technology and aims to help in developing next-generation cell-based therapies.

MaxCyte will provide the technology to CRISPR and receive milestone and sales-based payments and licensing fees.

Based in Switzerland, CRISPR Therapeutics is a gene-editing company, while MaxCyte is an American biotechnology company.

Dragonfly Therapeutics has expanded its previous four-target collaboration with Celgene for the discovery, development, and commercialisation of immunotherapies for solid and haematological cancers.

Four new targets have been added under the expanded agreement, increasing the total number of TriNKET immunotherapy drug candidates for in-licensing to eight.

The agreement means Celgene holds the licensing option for exclusive global intellectual property rights to the candidates developed using Dragonfly's TriNKET technology platform.

Licensing will be available to the company with an upfront payment of $50m, along with milestone and royalty bills.

Dragonfly Therapeutics and Celgene are both biotechnological companies based in the US.

Roivant Sciences has raised $200m in equity in a new financing round bringing the total funding raised by the company to approximately $7bn.

"Roivant Sciences has raised $200m in equity in a new financing round bringing the total funding raised by the company to approximately $7bn."

New investors NovaQuest Capital Management, RTW Investments, and other large institutional asset managers participated in the round along with the existing ones.

Roivant Sciences is a biopharmaceutical company based in the US.

Angion Biomedica has entered a partnership and license agreement with Sinovant Sciences for the former’s experimental small molecule BB3 in Greater China.

BB3 is a hepatocyte growth factor mimetic being developed for delayed graft function and acute kidney injury. It is currently being explored in Phase III trials.

Sinovant will receive exclusive license to develop, commercialise and manufacture BB3 in Greater China under the agreement.

Angion will be eligible to receive upfront and milestone-based payments, as well as royalties.

Angion Biomedica and Sinovant are both biopharmaceutical company based in the US and China respectively.

Harpoon Therapeutics has raised $70m in a series C equity financing round led by OrbiMed.

New investors Cormorant, Ridgeback Capital Investments, Lilly Asia Ventures (LAV), and NS Investment also participated in the round, along with existing investors MPM Capital, Oncology Impact Fund, Arix Bioscience, New Leaf Venture Partners, and Taiho Ventures.

The proceeds will be used to develop Harpoon’s immunotherapy programmes based on its TriTAC™ (Tri-specific T cell Activating Construct) and ProTriTAC (Protease-activated Tri-specific T Cell Activating Construct) platforms.

The platforms are being developed to innovate new therapies for cancer and other diseases using the immune system of patients.

Harpoon is a biotechnology company based in the US.